Five of these trials have shown superiority in reducing MACE compared to placebo, while all have confirmed the cardiovascular safety of GLP-1 RAs ( 4.3.1 Cardiovascular outcomes in GLP-1 RAs studies The ELIXA trial, which included 6068 patients, was the first to investigate the cardiovascular effects of GLP-1 RAs
By route of administration, the oral GLP-1 market is expected to witness a faster growth during 20262034
Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics
Hauser R, et al
Sources International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023 GLP-1 medicines in women with PCOS and obesity: meta-analysis of weight loss and hormonal outcomes GLP-1 medicines versus metformin in PCOS with overweight or obesity: systematic review and meta-analysis Semaglutide treatment of excess body weight in women with PCOS after lifestyle programs Semaglutide treatment in women with PCOS, obesity, and type 2 diabetes Semaglutide Prescribing Information (FDA, 2025) What Real Users Say About Tracking the PCOS Week PCOS Is Complex
Quienes prefieren formatos funcionales, fciles de consumir y con sabor agradable
